LEXINGTON, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Carol Satler, M.D, Ph.D. as senior vice president of medical and scientific affairs. Dr. Satler brings to AMAG more than 25 years of healthcare experience, including 15 years in the global biopharmaceutical industry and 10 years in clinical practice. Prior to joining AMAG, Dr. Satler served in executive clinical development and medical affairs roles at Pfizer and Sanofi, as well as Forest Labs and Millenium.
"Carol has a long track record of success in medical affairs that will be extremely valuable to AMAG," said William Heiden, president and chief executive officer of AMAG. "Through her 15-year career in the pharmaceutical industry, Carol has formulated and implemented medical affairs strategies and life cycle management plans for several major commercial products each with annual revenues in excess of $1 billion across a variety of indications. This experience will be invaluable to us as we prepare for the potential launch of Feraheme® for the treatment of iron deficiency anemia in a broader patient population, as well as other areas of future opportunity."
Dr. Satler has broad-based industry experience and has led and managed teams across several therapeutics areas. She has held leadership roles in medical affairs, clinical research and development and administration both in the U.S. and globally. Dr. Satler has successfully formulated strategic clinical development plans, life cycle management and commercialization of products. Dr. Satler received her medical degree and Ph.D. from Case Western Reserve University, completed her internship and residency, and practiced medicine at the Boston Children's Hospital with a focus on cardiology.Inducement Equity Awards In connection with Dr. Satler's entry into her employment agreement, effective on the first day of employment, Dr. Satler will be granted (i) an option to purchase 45,000 shares of common stock and (ii) 15,000 restricted stock units. The option will have an exercise price equal to the closing price of AMAG's common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in four equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts